Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Department of Applied Health Research, University College London, London, UK.
Med Decis Making. 2024 Feb;44(2):152-162. doi: 10.1177/0272989X231220954. Epub 2024 Jan 19.
Lung cancer clinical guidelines and risk tools often rely on smoking history as a significant risk factor. However, never-smokers make up 14% of the lung cancer population, and this proportion is rising. Consequently, they are often perceived as low-risk and may experience diagnostic delays. This study aimed to explore how clinicians make risk-informed diagnostic decisions for never-smokers.
Qualitative interviews were conducted with 10 lung cancer diagnosticians, supported by data from interviews with 20 never-smoker lung cancer patients. The data were analyzed using a framework analysis based on the Model of Pathways to Treatment framework and data-driven interpretations.
Participants described 3 main strategies for making risk-informed decisions incorporating smoking status: guidelines, heuristics, and potential harms. Clinicians supplemented guidelines with their own heuristics for never-smokers, such as using higher thresholds for chest X-ray. Decisions were easier for patients with high-risk symptoms such as hemoptysis. Clinicians worried about overinvestigating never-smoker patients, particularly in terms of physical and psychological harms from invasive procedures or radiation. To minimize unnecessary anxiety about lung cancer risk, clinicians made efforts to downplay this. Conversely, some patients found that this caused process harms such as delays and miscommunications.
Improved guidance and methods of risk differentiation for never-smokers are needed to avoid diagnostic delays, overreassurance, and clinical pessimism. This requires an improved evidence base and initiatives to increase awareness among clinicians of the incidence of lung cancer in never-smokers. As the proportion of never-smoker patients increases, this issue will become more urgent.
Smoking status is the most common risk factor used by clinicians to guide decision making, and guidelines often focus on this factor.Some clinicians also use their own heuristics for never-smokers, and this becomes particularly relevant for patients with lower risk symptoms.Clinicians are also concerned about the potential harms and risks associated with deploying resources on diagnostics for never-smokers.Some patients find it difficult to decide whether or not to go ahead with certain procedures due to efforts made by clinicians to downplay the risk of lung cancer.Overall, the study highlights the complex interplay between smoking history, clinical decision making, and patient anxiety in the context of lung cancer diagnosis and treatment.
肺癌临床指南和风险工具通常将吸烟史作为一个重要的风险因素。然而,从不吸烟者占肺癌患者的 14%,而且这个比例还在上升。因此,他们通常被认为是低风险人群,可能会经历诊断延迟。本研究旨在探讨临床医生如何为从不吸烟者做出知情风险的诊断决策。
对 10 名肺癌诊断医生进行了定性访谈,并结合 20 名从不吸烟者肺癌患者的访谈数据进行了支持。数据采用基于治疗途径模型的框架分析和数据驱动的解释方法进行分析。
参与者描述了将吸烟状况纳入风险知情决策的 3 种主要策略:指南、启发式和潜在危害。临床医生使用自己的启发式方法来补充从不吸烟者的指南,例如使用更高的胸部 X 光阈值。对于有高风险症状(如咯血)的患者,决策更容易。临床医生担心对从不吸烟者患者进行过度检查,特别是考虑到侵入性程序或辐射对身体和心理的危害。为了尽量减少对肺癌风险的不必要焦虑,临床医生努力淡化这一点。相反,一些患者发现这会导致流程上的伤害,例如延误和沟通不畅。
需要改进针对从不吸烟者的指导和风险区分方法,以避免诊断延迟、过度保证和临床悲观情绪。这需要更好的证据基础,并采取措施提高临床医生对从不吸烟者肺癌发病率的认识。随着从不吸烟者患者比例的增加,这个问题将变得更加紧迫。
吸烟状况是临床医生指导决策最常用的风险因素,指南通常侧重于这一因素。一些临床医生还为从不吸烟者使用自己的启发式方法,对于风险较低的症状患者,这一点尤其相关。临床医生还担心在为从不吸烟者进行诊断时部署资源相关的潜在危害和风险。一些患者由于临床医生努力淡化肺癌风险,发现很难决定是否进行某些程序。总的来说,本研究强调了在肺癌诊断和治疗背景下,吸烟史、临床决策和患者焦虑之间的复杂相互作用。